Jg. Porterfield et al., EXPERIENCE WITH 3 DIFFERENT 3RD-GENERATION CARDIOVERTER-DEFIBRILLATORS IN PATIENTS WITH CORONARY-ARTERY DISEASE OR CARDIOMYOPATHY, The American journal of cardiology, 72(3), 1993, pp. 301-304
Clinical investigations are being performed in multiprogrammable devic
es whose therapeutic options include antitachycardia pacing, cardiover
sion, defibrillation and bradycardia pacing. Three different third-gen
eration devices were implanted in 46 research patients at 1 clinical c
enter to document their safety and efficacy for the treatment of malig
nant ventricular arrhythmias. Additionally, the purpose of the study w
as to determine if antitachycardia pacing is a desirable and frequentl
y used feature of tiered devices. The Medtronic PCD was implanted in 1
5 patients (12 men, mean age 60 +/- 13 years, mean ejection fraction 4
0 +/- 15%), the Ventritex Cadence in 21 patients (17 men, mean age 65
+/- 10 years, mean ejection fraction 38 +/- 12%), and the CPI VENTAK P
Rx in 10 patients (8 men, mean age 63 +/- 14 years, mean ejection frac
tion 31 +/- 8%). All patients presented with cardiac arrest or ventric
ular tachycardia. During follow-up of 10 +/- 6 months (range 1 to 19),
70% of the 20 patients with antitachycardia pacing activated used the
feature for spontaneous ventricular tachycardia. The antitachycardia
pacing parameters were reprogrammed 20 times in 15 patients. Two thous
and six hundred thirty-eight of 2,675 (98%) antitachycardia pacing att
empts successfully terminated spontaneous tachyarrhythmias. Low-energy
cardioversion or defibrillation terminated tachyarrhythmias in patien
ts where pacing was unsuccessful. One hundred forty-eight episodes of
tachycardia were successfully treated directly by shocks in 16 of 46 p
atients (35%). There were no deaths due to device failure. This initia
l single-center clinical experience suggests that the PCD, Cadence and
VENTAK PRx are all safe and effective tiered therapy devices for the
treatment of malignant ventricular arrhythmias. Antitachycardia pacing
successfully terminated most episodes of ventricular tachycardia; in
patients with this feature activated, it was used frequently but requi
red reprogramming to achieve high levels of success.